Koneksa Appoints Dr. Jessie Bakker as Vice President of Clinical Development

NEW YORK–(BUSINESS WIRE)–#biotech—Koneksa, the evidence-based digital biomarkers company, today announced the appointment of Jessie Bakker, M.S., Ph.D., as Vice President (VP) of Clinical Development. She brings a wealth of experience that will play a pivotal role in shaping Koneksa’s clinical program strategy from development through life-cycle management.

Dr. Bakker brings more than 15 years of expertise in digital health technology to Koneksa, including her recent role as VP of Digital Measures and Diagnostics at the Digital Medicine Society (DiMe). Dr. Bakker has extensive experience in the development, validation, and deployment of digital tools in clinical trials within academia as well as with several device manufacturers. She is a founding member of DiMe, served as co-chair of the DiMe research committee from 2019-2021, and contributed to DiMe’s first project, which developed the V3 framework as a means of evaluating sensor-based digital health technologies as being fit-for-purpose.

Prior to DiMe, Dr. Bakker held faculty positions at the Division of Sleep and Circadian Disorders at Brigham and Women’s Hospital and the Division of Sleep Medicine at Harvard Medical School. Dr. Bakker also has technology industry experience and held positions at Signifier Medical Technologies as the Executive Vice President of Medical Affairs, and at Philips Sleep and Respiratory Care as the Associate Director of Clinical Affairs. She started her career at the University of Otago, New Zealand, where she completed a Ph.D. in Medicine before completion of a postdoctoral fellowship at Harvard. Dr. Bakker also completed a B.S. in Neuroscience at the University of Sydney and a M.S. in Neuroscience at the University of Otago.

“Jessie’s compelling and extensive background in digital health technology, including the development, validation, and implementation of digital measurement and diagnostic tools, will be invaluable as we advance our digital biomarker programs,” said John Wagner, M.D, Ph.D., Chief Medical Officer, Koneksa. “Jessie brings considerable expertise in the clinical development and validation of digital biomarkers, particularly in sleep, and we’re thrilled to welcome her to the Koneksa team.”

“I’ve long admired the scientific approach that Koneksa has taken, and am excited to join the team and leverage my experience to advance Koneksa’s pipeline of evidence-based digital biomarkers and accelerate clinical research and improve patient outcomes,” said Dr. Bakker.

About Koneksa

Koneksa is a healthcare technology company pioneering evidence-based digital biomarkers to accelerate clinical research and guide decision-making in drug development and market strategy. Our evidence-based biomarker solutions enable efficient clinical trial designs to help innovative therapies reach patients faster. Koneksa aims to revolutionize treatment effect detection in clinical research and improve patient outcomes. Learn more at koneksahealth.com.

Contacts

Media
Kimberly Ha

KKH Advisors

917-291-5744

kimberly.ha@kkhadvisors.com